Last reviewed · How we verify

Benign prostatic hyperplasia — Treatment Landscape & Competitive Intelligence

Benign prostatic hyperplasia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Benign prostatic hyperplasia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Rapaflo SILODOSIN AbbVie alpha-Adrenergic Blocker [EPC] alpha-1 adrenoreceptors 2008-01-01
Uroxatral ALFUZOSIN Advanz alpha-Adrenergic Blocker alpha 1-adrenoreceptors 2003-01-01
Avodart dutasteride GSK (GlaxoSmithKline) 5-alpha-reductase inhibitor (dual) 3-oxo-5-alpha-steroid 4-dehydrogenase 1, 3-oxo-5-alpha-steroid 4-dehydrogenase 2, Glycine receptor subunit alpha-1 2001-11-20
Flivas NAFTOPIDIL Asahi Kasei naftopidil Alpha-1D adrenergic receptor 1999-01-01
Propecia finasteride Merck & Co. 5-alpha-reductase inhibitor 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1, Cytochrome P450 2C19, Cytochrome P450 2C9 1992-06-19
Cardura DOXAZOSIN Viatris alpha-Adrenergic Blocker Alpha-1B adrenergic receptor 1990-01-01
Cialis Cialis Ottawa Hospital Research Institute Nuclear receptor subfamily 2 group E member 1, Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Potassium voltage-gated channel subfamily H member 2
Avodart Avodart GlaxoSmithKline 3-oxo-5-alpha-steroid 4-dehydrogenase 1, 3-oxo-5-alpha-steroid 4-dehydrogenase 2, Glycine receptor subunit alpha-1
Flomax tamsulosin Boehringer Ingelheim 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 7, Alpha-1A adrenergic receptor
Cialis tadalafil Eli Lilly Phosphodiesterase 5 Inhibitor [EPC] Nuclear receptor subfamily 2 group E member 1, Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Potassium voltage-gated channel subfamily H member 2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Benign prostatic hyperplasia
  2. AbbVie · 1 drug in Benign prostatic hyperplasia
  3. Advanz · 1 drug in Benign prostatic hyperplasia
  4. Asahi Kasei · 1 drug in Benign prostatic hyperplasia
  5. Boehringer Ingelheim · 1 drug in Benign prostatic hyperplasia
  6. Eli Lilly · 1 drug in Benign prostatic hyperplasia
  7. GSK (GlaxoSmithKline) · 1 drug in Benign prostatic hyperplasia
  8. GlaxoSmithKline · 1 drug in Benign prostatic hyperplasia
  9. Merck & Co. · 1 drug in Benign prostatic hyperplasia
  10. Ottawa Hospital Research Institute · 1 drug in Benign prostatic hyperplasia
  11. University of Iowa · 1 drug in Benign prostatic hyperplasia
  12. Viatris · 1 drug in Benign prostatic hyperplasia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Benign prostatic hyperplasia:

Cite this brief

Drug Landscape (2026). Benign prostatic hyperplasia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/benign-prostatic-hyperplasia. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing